Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0013395 (dyspepsia)
 4,879 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Indolent systemic mastocytosis (SM) patients have a varied clinical presentation, ranging from predominantly cutaneous symptoms to recurrent systemic symptoms (eg, flushing, palpitations, dyspepsia, diarrhea, bone pain) that can be severe and potentially life threatening (anaphylaxis). Mastocytosis patients without skin involvement pose a diagnostic challenge; a high index of suspicion is needed in those with mast cell-degranulation symptoms, including anaphylaxis following Hymenoptera stings or other triggers. Modern-era molecular and flow-cytometric diagnostic methods are very sensitive and can detect minimal involvement of bone marrow with atypical/clonal mast cells; in some cases, full diagnostic criteria for SM are not fulfilled. An important aspect of treatment is avoidance of known symptom triggers; other treatment principles include a stepwise escalation of antimediator therapies and consideration of cytoreductive therapies for those with treatment-refractory symptoms. The perioperative management of mastocytosis patients is nontrivial; a multidisciplinary preoperative assessment, adequate premedications, and close intra- and postoperative monitoring are critical. Smoldering mastocytosis is a variant with high systemic mast cell burden. While its clinical course can be variable, there is greater potential need for cytoreductive therapies (eg, interferon-alpha, cladribine) in this setting. A systematic approach to the diagnosis and treatment of indolent SM using a case-based approach of representative clinical scenarios is presented here.
 ...
PMID:How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). 2342 50

High-resolution (HR) mapping of the gastrointestinal (GI) bioelectrical activity is an emerging method to define the GI dysrhythmias such as gastroparesis and functional dyspepsia. Currently, there is no solution available to conduct HR mapping in long-term studies. We have developed an implantable 64-channel closed-loop near-field communication system for real-time monitoring of gastric electrical activity. The system is composed of an implantable unit (IU), a wearable unit (WU), and a stationary unit (SU) connected to a computer. Simultaneous data telemetry and power transfer between the IU and WU is carried out through a radio-frequency identification (RFID) link operating at 13.56 MHz. Data at the IU are encoded according to a self-clocking differential pulse position algorithm, and load shift keying modulated with only 6.25% duty cycle to be back scattered to the WU over the inductive path. The retrieved data at the WU are then either transmitted to the SU for real-time monitoring through an ISM-band RF transceiver or stored locally on a micro SD memory card. The measurement results demonstrated successful data communication at the rate of 125 kb/s when the distance between the IU and WU is less than 5 cm. The signals recorded in vitro at IU and received by SU were verified by a graphical user interface.
 ...
PMID:An Implantable Inductive Near-Field Communication System with 64 Channels for Acquisition of Gastrointestinal Bioelectrical Activity. 3123 21